Trial reportScientific reports2025
Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of antibacterial prophylaxis in non-Hodgkin lymphoma (NHL) patients undergoing Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisolone (R-CHOP) chemotherapy with granulocyte-colony stimulating factor (G-CSF) support remains uncertain. This study evaluates the efficacy of levofloxacin in preventing febrile episodes in these patients. A randomized, single-blind, placebo-controlled trial was conducted, enrolling NHL patients receiving R-CHOP every 21-day cycle between January 2023 and June 2024. Patients were randomized to receive levofloxacin 500 mg once daily or placebo from day 1 to day 7 post-chemotherapy. All patients received G-CSF support. The primary outcome was the occurrence of febrile episodes within 120 days. Eighty participants were equally randomized into two groups. The median age was 64 years. In the intention-to-treat analysis, the first febrile episode was documented in 3 (7.5%) and 12 (30%) participants in the levofloxacin and placebo groups, respectively (P = 0.010). Levofloxacin prophylaxis significantly reduced febrile neutropenia (2.5% vs. 20%, P = 0.029) and the composite of febrile episodes, septic shock, all-cause mortality and chemotherapy dose reduction (10% vs. 30%, P = 0.025). The hazard ratio (HR) for fever-free survival with levofloxacin prophylaxis was 0.23 (95% CI 0.06-0.80; P = 0.012). Multivariate analysis showed levofloxacin was associated with a lower risk of febrile episodes (adjusted HR 0.17, 95% CI, 0.05-0.66; P = 0.01). No differences in mortality or serious adverse events were observed. Levofloxacin prophylaxis is an effective, well-tolerated strategy to reduce febrile episodes, febrile neutropenia and composite adverse outcomes after R-CHOP chemotherapy, despite concurrent G-CSF support. Long-term antibiotic resistance monitoring is warranted. Trial registration: This trial is registered at Thai Clinical Trials Registry (TCTR), number TCTR20230719005.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.